API share price (ASX:API) falls after rejecting Wesfarmers takeover offer

API said no deal to Wesfarmers this morning.

| More on:
Three pills with faces showing sad to happy, indicating a rising share price for an ASX pharmaceutical company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian Pharmaceutical Industries Ltd (ASX: API) share price is in the red after it rejected Wesfarmers Ltd's (ASX: WES) takeover offer.

API announced this morning its board has rejected the offer, saying it's not compelling or in its shareholders' best interests.

Right now, the API share price is $1.40, 0.35% lower than its previous closing price.

Let's take a closer look at the news out of API this morning.

Wesfarmers' offer rejected

The API share price is down today after the company rejected Wesfarmers' takeover offer of $1.38 cash per share.

The pharmaceutical, health, and beauty-focused company said Wesfarmers' offer was at an 18.7% premium to API's 3-month volume weighted average share price. It said that figure is "significantly below the Australian market average for transactions of this nature".

Additionally, API's board said the offer was opportunistic given the impact COVID-19 has had on API's profits.

It also said it failed to take into account the strategic value of Priceline.

According to API, its expecting "substantial" growth in Priceline's earnings as COVID-19 restrictions lessen and the impact of closing 9 loss-making stores take effect.

It also said Wesfarmers' offer failed to take into account API's investment into 39 Clear Skincare clinics and the savings expected from the development of the Marsden Park Distribution Centre.

Finally, it said it expects its pharmaceutical distribution business to get more funding from the 4 years remaining on API's 7th Community Pharmacy Agreement, as well as its arrangement with Pfizer (which doesn't include the COVID-19 vaccine).

The Wesfarmers share price is falling alongside that of API this morning.

Currently, shares in Wesfarmers are going for $61.25, 0.49% lower than their previous close.

API share price snapshot

API has been performing well on the ASX lately.

Right now, shares in API are trading for 11.9% more than they were at the start of the year. They've also gained 29% since this time last year.

The company has a market capitalisation of around $694 million, with approximately 492 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Wesfarmers Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »